N@N

MEDICINES COMPANY (NASDAQ:MDCO), Up By 12.64% ($2.03) From $16.060 After BUYINS.NET Report Predicted Strength After Earnings

^{Published on 2011-05-26 13:21:19 - WOPRAI}
 

May 26, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, April 26th 2011 stating that MEDICINES COMPANY (NASDAQ:MDCO) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=mdco&id=162853

At the time this story was written, MEDICINES COMPANY (NASDAQ:MDCO) is Up By 12.64% ($2.03) From $16.060 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

MEDICINES COMPANY (NASDAQ:MDCO) - The Medicines Company operates as a global pharmaceutical company with a focus on advancing the treatment of critical care patients. The company markets Angiomax for use in patients undergoing coronary angioplasty; and Cleviprex, an injectable emulsion for the reduction of blood pressure. Its developing products include Cangrelor, an antiplatelet agent, which is in phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin that is in phase III clinical trial acts as an antibiotic for the treatment of serious gram-positive bacterial infections, including ABSSSI; and Argatroban, a phase III and NDA filed direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis. The Medicines Companys developing products also include CU2010, which is in phase I clinical trial that acts as a serine protease inhibitor for the reduction of blood loss during surgery; and ApoA-I Milano, a phase I clinical trial product for the reversal of atherosclerotic plaque development and reduction of the risk of coronary events in patients with ACS. The company sells its products through sales representatives and managers. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MEDICINES COMPANY (NASDAQ:MDCO) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net